Dec 9 (Reuters) - CVS Health (CVS) on Tuesday forecast 2026 profit above Wall Street estimates and this year's projected earnings, signalling steady progress in the health conglomerate's turnaround plan.
CVS stock rose 5% in early trading on Tuesday.
The company in October projected double-digit earnings growth for 2026 after raising its 2025 profit forecast for the third time.
"We are closing out 2025 with meaningful momentum across our businesses and we expect another year of strong earnings growth in 2026," said Chief Financial Officer Brian Newman on Tuesday.
The company forecast 2026 adjusted profit to be in the range of $7.00 to $7.20 per share, compared with analysts' average estimate of $7.16, according to data compiled by LSEG.
It, however, expects total revenue of at least $400 billion next year, below analysts' average estimate of $419.26 billion.
CVS also raised its 2025 adjusted profit forecast to $6.60 to $6.70 per share from $6.55 to $6.65 previously.
(Reporting by Sneha S K in Bengaluru; Editing by Shinjini Ganguli)
LATEST POSTS
- 1
Holiday spots Well known With Americans In 2024 - 2'Supergirl' drops 1st teaser trailer: Watch Milly Alcock as Kara Zor-El and the return of Krypto the Superdog
- 3The Best Games On the planet
- 435 million tons of food go to waste yearly in the US. Experts share tips to help stop it
- 5Netanyahu expects Iran's leadership to fall
- US measles cases surpass 2,000, highest in 30 years: CDC
- Chicago reports first rabies-positive dog in 61 years. What we know.
- Greece eyes migrant repatriation centres outside the EU
- Dental Embed Developments: Upsetting Current Dentistry
- Rediscovering Euphoria: Individual Accounts of Conquering Despondency
- It's your last chance to subscribe to Paramount+ before they raise their prices: Here's how to lock in current pricing
- The most effective method to Engage in Local area Making arrangements for 5G Pinnacle Establishments
- Creative Tech Contraptions That Will Work on Your Life
- Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial
